Smart Nanodevice Combined Tumor-Specific Vector with Cellular Microenvironment-Triggered Property for Highly Effective Antiglioma Therapy
- 7 January 2014
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 8 (2) , 1191-1203
Abstract
Malignant glioma, a highly aggressive tumor, is one of the deadliest types of cancer associated with dismal outcome despite optimal chemotherapeutic regimens. One explanation for this is the failure of most chemotherapeutics to accumulate in the tumors, additionally causing serious side effects in periphery. To solve these problems, we sought to develop a smart therapeutic nanodevice with cooperative dual characteristics of high tumor-targeting ability and selectively controlling drug deposition in tumor cells. This nanodevice was fabricated with a cross-linker, containing disulfide linkage to form an inner cellular microenvironment-responsive “-S-S-” barrier, which could shield the entrapped drug leaking in blood circulation. In addition, dehydroascorbic acid (DHA), a novel small molecular tumor-specific vector, was decorated on the nanodevice for tumor-specific recognition via GLUT1, a glucose transporter highly expressed on tumor cells. The drug-loaded nanodevice was supposed to maintain high integrity in the bloodstream and increasingly to specifically bind with tumor cells through the association of DHA with GLUT1. Once within the tumor cells, the drug release was triggered by a high level of intracellular glutathione. When these two features were combined, the smart nanodevice could markedly improve the drug tumor-targeting delivery efficiency, meanwhile decreasing systemic toxicity. Herein, this smart nanodevice showed promising potential as a powerful platform for highly effective antiglioma treatment.Keywords
This publication has 54 references indexed in Scilit:
- Expression and/or activity of the SVCT2 ascorbate transporter may be decreased in many aggressive cancers, suggesting potential utility for sodium bicarbonate and dehydroascorbic acid in cancer therapyMedical Hypotheses, 2013
- Tumor-Targeting and Microenvironment-Responsive Smart Nanoparticles for Combination Therapy of Antiangiogenesis and ApoptosisACS Nano, 2013
- In Vitro Efficacy of Paclitaxel-Loaded Dual-Responsive Shell Cross-Linked Polymer Nanoparticles Having Orthogonally Degradable Disulfide Cross-Linked Corona and Polyester Core DomainsMolecular Pharmaceutics, 2013
- Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implicationsExperimental Cell Research, 2012
- The distribution and retention of paclitaxel and doxorubicin in multicellular layer culturesOncology Reports, 2012
- Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targetingInternational Journal of Nanomedicine, 2012
- Choline‐Derivate‐Modified Nanoparticles for Brain‐Targeting Gene DeliveryAdvanced Materials, 2011
- Phosphatidylserine targeting for diagnosis and treatment of human diseasesApoptosis, 2010
- Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseasesNeurobiology of Disease, 2010
- On the Origin of Cancer CellsScience, 1956